Literature DB >> 11378537

VLA-4-dependent myeloma cell adhesion.

F Sanz-Rodríguez1, J Teixidó.   

Abstract

In multiple myeloma, the malignant plasma cells in the bone marrow attach to stromal elements using several adhesion receptors. The integrin VLA-4 plays a major role in mediating myeloma cell adhesion to the stroma, by interacting with its ligands VCAM-1 and fibronectin. VLA-4, as well as other integrins, can be expressed in different states of activation, which convey different levels of adhesion. Modulation of VLA-4 adhesive activity by external stimuli has been demonstrated for hematopoietic progenitor cells and lymphocytes, and can represent a potential mechanism contributing to the localization of myeloma cells in the bone marrow. In this review we have summarized data on the characterization of VLA-4-mediated myeloma cell adhesion, and we present potential mechanisms of modulation of VLA-4 activity. In addition, we also speculate on the signalling generated upon interaction of myeloma VLA-4 with its ligands on the survival of these cells in the bone marrow.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11378537     DOI: 10.3109/10428190109057979

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  15 in total

1.  Definition of a multiple myeloma progenitor population in mice driven by enforced expression of XBP1s.

Authors:  Joshua Kellner; Caroline Wallace; Bei Liu; Zihai Li
Journal:  JCI Insight       Date:  2019-04-04

2.  CD28-mediated regulation of multiple myeloma cell proliferation and survival.

Authors:  Nizar J Bahlis; Anne M King; Despina Kolonias; Louise M Carlson; Hong Yu Liu; Mohamad A Hussein; Howard R Terebelo; Gerald E Byrne; Bruce L Levine; Lawrence H Boise; Kelvin P Lee
Journal:  Blood       Date:  2007-02-20       Impact factor: 22.113

3.  RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma.

Authors:  Abdel Kareem Azab; Feda Azab; Simona Blotta; Costas M Pitsillides; Brian Thompson; Judith M Runnels; Aldo M Roccaro; Hai T Ngo; Molly R Melhem; Antonio Sacco; Xiaoying Jia; Kenneth C Anderson; Charles P Lin; Barrett J Rollins; Irene M Ghobrial
Journal:  Blood       Date:  2009-05-14       Impact factor: 22.113

4.  Increased signaling through p62 in the marrow microenvironment increases myeloma cell growth and osteoclast formation.

Authors:  Yuko Hiruma; Tadashi Honjo; Diane F Jelinek; Jolene J Windle; Jaekyoon Shin; G David Roodman; Noriyoshi Kurihara
Journal:  Blood       Date:  2009-03-12       Impact factor: 22.113

5.  Ex Vivo and In Vivo Evaluation of Overexpressed VLA-4 in Multiple Myeloma Using LLP2A Imaging Agents.

Authors:  Deepti Soodgupta; Haiying Zhou; Wissam Beaino; Lan Lu; Michael Rettig; Mark Snee; James Skeath; John F DiPersio; Walter J Akers; Richard Laforest; Carolyn J Anderson; Michael H Tomasson; Monica Shokeen
Journal:  J Nucl Med       Date:  2016-01-07       Impact factor: 10.057

6.  Rationally engineered nanoparticles target multiple myeloma cells, overcome cell-adhesion-mediated drug resistance, and show enhanced efficacy in vivo.

Authors:  T Kiziltepe; J D Ashley; J F Stefanick; Y M Qi; N J Alves; M W Handlogten; M A Suckow; R M Navari; B Bilgicer
Journal:  Blood Cancer J       Date:  2012-04-20       Impact factor: 11.037

7.  Proteomic analysis of α4β1 integrin adhesion complexes reveals α-subunit-dependent protein recruitment.

Authors:  Adam Byron; Jonathan D Humphries; Sue E Craig; David Knight; Martin J Humphries
Journal:  Proteomics       Date:  2012-07       Impact factor: 3.984

8.  VLA4-Targeted Nanoparticles Hijack Cell Adhesion-Mediated Drug Resistance to Target Refractory Myeloma Cells and Prolong Survival.

Authors:  Francesca Fontana; Michael J Scott; John S Allen; Xiaoxia Yang; Grace Cui; Dipanjan Pan; Noriko Yanaba; Mark A Fiala; Julie O'Neal; Anne H Schmieder-Atteberry; Julie Ritchey; Michael Rettig; Kathleen Simons; Steven Fletcher; Ravi Vij; John F DiPersio; Gregory M Lanza
Journal:  Clin Cancer Res       Date:  2020-12-22       Impact factor: 13.801

Review 9.  Novel Agents and Future Perspectives on Theranostics.

Authors:  Lilja B Solnes; Monica Shokeen; Neeta Pandit-Taskar
Journal:  Semin Radiat Oncol       Date:  2021-01       Impact factor: 5.934

10.  Very late antigen-4 (α(4)β(1) Integrin) targeted PET imaging of multiple myeloma.

Authors:  Deepti Soodgupta; Michelle A Hurchla; Majiong Jiang; Alexander Zheleznyak; Katherine N Weilbaecher; Carolyn J Anderson; Michael H Tomasson; Monica Shokeen
Journal:  PLoS One       Date:  2013-02-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.